BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 23232855)

  • 1. A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease.
    Chen D; Bachanova V; Ketterling RP; Begna KH; Hanson CA; Viswanatha DS
    Am J Surg Pathol; 2013 Jan; 37(1):147-51. PubMed ID: 23232855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response of monoblastic myeloid sarcoma with FIP1L1- PDGFRA rearrangement to imatinib monotherapy.
    Srinivas U; Barwad A; Pubbaraju SV
    Br J Haematol; 2014 Jun; 165(5):583. PubMed ID: 24456122
    [No Abstract]   [Full Text] [Related]  

  • 3. Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.
    Barraco D; Carobolante F; Candoni A; Simeone E; Piccaluga P; Tabanelli V; Fanin R
    Eur J Haematol; 2014 Jun; 92(6):541-5. PubMed ID: 24460680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia.
    Wang J; Zhang Q; Zeng H; Chen B; Ouyang J
    Pharmacogenomics; 2016; 17(2):99-102. PubMed ID: 26666578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia.
    Shah S; Loghavi S; Garcia-Manero G; Khoury JD
    J Hematol Oncol; 2014 Mar; 7():26. PubMed ID: 24669761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
    Rathe M; Kristensen TK; Møller MB; Carlsen NL
    Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
    Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
    Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.
    Uchida T; Kitaura J; Nakahara F; Togami K; Inoue D; Maehara A; Nishimura K; Kawabata KC; Doki N; Kakihana K; Yoshioka K; Izawa K; Oki T; Sada A; Harada Y; Ohashi K; Katayama Y; Matsui T; Harada H; Kitamura T
    Exp Hematol; 2014 May; 42(5):369-379.e3. PubMed ID: 24486648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
    Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
    Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 32-year-old man with persistent cough, shortness of breath, eosinophilic pneumonia, and peripheral blood eosinophilia. Myeloid neoplasm associated with eosinophilia and platelet-derived growth factor receptor-alpha rearrangement.
    Hossain NM; Jain N; Steinmetz JL; McConville JF; Anastasi J; Odenike O
    Chest; 2012 Dec; 142(6):1680-1683. PubMed ID: 23208343
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of FIP1L1-PDGFRA fusion by FISH.
    Ma ES; Wong KF; Wong CL; Siu LL
    Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
    [No Abstract]   [Full Text] [Related]  

  • 12. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
    Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G
    Haematologica; 2007 Sep; 92(9):1173-9. PubMed ID: 17666373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.
    Pardanani A; Ketterling RP; Li CY; Patnaik MM; Wolanskyj AP; Elliott MA; Camoriano JK; Butterfield JH; Dewald GW; Tefferi A
    Leuk Res; 2006 Aug; 30(8):965-70. PubMed ID: 16406016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
    Helbig G; Kyrcz-Krzemień S
    Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
    [No Abstract]   [Full Text] [Related]  

  • 15. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
    Ng HJ; Tan DC; Yiu RC; How GF
    Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete response of myeloid sarcoma with FIP1L1-PDGFRA -associated myeloproliferative neoplasms to imatinib mesylate monotherapy.
    Tang TC; Chang H; Chuang WY
    Acta Haematol; 2012; 128(2):83-7. PubMed ID: 22722648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
    La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
    Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement.
    Jain N; Khoury JD; Pemmaraju N; Kollipara P; Kantarjian H; Verstovsek S
    Blood; 2013 Nov; 122(19):3387-8. PubMed ID: 24203930
    [No Abstract]   [Full Text] [Related]  

  • 19. Generalized Eruptive Histiocytosis Associated With FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia.
    Ziegler B; Peitsch WK; Reiter A; Marx A; Goerdt S; Géraud C
    JAMA Dermatol; 2015 Jul; 151(7):766-9. PubMed ID: 25923837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].
    Martinaud C; Souraud JB; Cournac JM; Pons S; Ménard G; de Jaureguiberry JP; Brisou P
    Rev Med Interne; 2011 May; 32(5):e66-8. PubMed ID: 20633965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.